BB Biotech: Investing in medical research which changes lives
Analyst and Portfolio Manager at BB Biotech since 2014. Dr. Koch previously worked as a sell-side Pharma & Biotech Equity Analyst at Bank am Bellevue and Research Associate at the Institute of Pharmaceutical Sciences, ETH Zurich. He holds a PhD in Chemoinformatics & Computational Drug Design from ETH Zurich and a Masters in Bioinformatics from Goethe University Frankfurt.
The missing link between sovereigns and corporates
Sovereigns and corporate fixed income investments are inextricably linked through economic and market forces. Too often a country’s economic risk profile can be mispriced in fixed income markets due segmentation of these sectors
Exploiting the rule-based investor
The proliferation of smart beta in equity, leads to the question of whether smart strategies can be utilised in fixed income. Rules based investors are often the source of inefficiency in fixed income markets and to us a smart strategy requires an active component